报价延迟最少15分钟:2026/04/29 02:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.78 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.22/0.54
|
|
企业价值
29.44M
|
| 资产负债 |
|
每股账面净值
-0.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.73M
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring. |
